CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0000789: InfertilityHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (8)


Name (Synonyms) Correlation
drug1054 Exposure: Covid-19 infection Wiki 0.38
drug3226 cleavage-stage embryo transfer Wiki 0.38
drug1177 Generalized Anxiety Disorder-7 (GAD-7) Wiki 0.38
drug2065 Patient Health Questionnaire-9 (PHQ-9) Wiki 0.38
drug3203 blastocyst-stage embryo transfer Wiki 0.38
drug1981 Online questionnaire Wiki 0.19
drug2311 Questionnaire Wiki 0.15
drug443 Blood sample Wiki 0.12

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D007246 Infertility NIH 1.00
D007247 Infertility, Female NIH 0.38
D007248 Infertility, Male NIH 0.38

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0003251 Male infertility HPO 0.38
HP:0008222 Female infertility HPO 0.38

There are 7 clinical trials

Clinical Trials


1 Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer: A Multicenter, Prospective, Randomized Controlled Trial

The aim of this RCT is to compare differences in the efficacy and safety between cleavage-stage embryo transfer and blastocyst-stage embryo transfer in IVF/ICSI treatment cycle, taking into account of subsequent vitrified embryo transfers. Subjects with 3 or more transferrable cleavage embryos will be randomized to the cleavage-stage or blastocyst-stage embryos transfer group. The primary outcome is cumulative live birth rate (CLBR) per patient until the first live birth from one initiated oocyte retrieval cycle, calculated using outcomes from the first three embryo transfers within 1 year after randomization.

NCT03152643 Infertility Procedure: blastocyst-stage embryo transfer Procedure: cleavage-stage embryo transfer
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Description: Cumulative live birth rate (CLBR) is defined the first live birth per patient from one initiated oocyte retrieval cycle(Calculated using outcomes from the first three embryo transfers within 1 year after randomization). Live birth is defined as delivery of any neonate ≥24 weeks gestation with heart beat and breath.

Measure: cumulative live birth rate

Time: 30 months

Secondary Outcomes

Description: Biochemical pregnancy is defined as a serum β-HCG level of at least 25 IU/L 14 days after embryo transfer.

Measure: biochemical pregnancy rate

Time: 30 months

Description: Clinical pregnancy is defined by the presence of intrauterine gestation sacs at 30-35 days after embryo transfer.

Measure: clinical pregnancy rate

Time: 30 months

Description: Ongoing pregnancy is defined as a viable pregnancy at 12 weeks gestation.

Measure: ongoing pregnancy rate

Time: 30 months

Description: Pregnancy loss is defined as a pregnancy that results in a spontaneous abortion or therapeutic abortion that occurred throughout pregnancy.

Measure: Pregnancy loss rate

Time: 30 months

Description: Number of patients with moderate or severe OHSS/ number of COS cycles.

Measure: moderate or severe OHSS rate

Time: 12 months

Description: diagnosed by ultrasound examination or laparoscopic surgery visualizing more than or equal to 1 gestational sacs outside the uterus or by abnormally increasing serum hCG level without sonographic visualization and the absence of chorionic villi inside the uterus after uterine curettage, which was treated by methotrexate.

Measure: ectopic pregnancy

Time: 24 months

Description: the ratio of males to females in the newborns

Measure: sex ratio

Time: 30 months

Description: Number of multiple pregnancies / number of clinical pregnancies.

Measure: multiple pregnancy

Time: 30 months

Description: Number of pregnancies with complications / number of pregnancies; ;number of live births with neonatal complications / number of live births

Measure: incidence of obstetric and perinatal complications

Time: 30 months

Description: structural or functional anomalies that occur during intrauterine life and can be identified prenatally, at birth or later in life.

Measure: congenital anomalies

Time: 30 months

Description: the number of gestational sacs detected with sonography at 6 weeks of pregnancy/the number of embryos transferred

Measure: implantation rate

Time: 30 months

Description: Weight of newborns at delivery

Measure: Birth weight

Time: 30 months

2 Impact of COVID-19 Pandemic on the Psychological Status of Infertile Patients Who Had in Vitro Fertilization Treatment Interrupted or Postponed

Infertility is a severely distressing experience for many couples. Depression and anxiety are psychological disorders associated with infertility, and they may worsen during infertility treatments. This study times to understand the changes in the psychological status of infertile patients who had in vitro fertilization (IVF) treatment interrupted or postponed because of the COVID-19 pandemic.

NCT04395755 Infertility, Female ART IVF COVID-19 Behavioral: Generalized Anxiety Disorder-7 (GAD-7) Behavioral: Patient Health Questionnaire-9 (PHQ-9)
MeSH:Infertility Infertility, Female
HPO:Female infertility Infertility

Primary Outcomes

Measure: Severity of anxiety

Time: 1-4 weeks after communication of interrupted or delayed IVF

Measure: Severity of depression

Time: 1-4 weeks after communication of interrupted or delayed IVF

3 Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic

The COVID-19 pandemic brought new challenges to our nationwide healthcare system, with rapid escalation of the number of affected individuals over a handful of weeks. From March 13, a first set of measures was taken to minimise the spread of the virus, which largely impacted societal and economical daily life. A view days later, on March 17, the country was put in "lockdown" and all non-urgent medical treatments were cancelled or postponed. As recommended by the major scientific fertility societies, all non-ivf fertility treatments were discontinued abruptly, whereas started ivf stimulations were continued until oocyte aspiration, where after a freeze-all strategy was applied. There is little information available for women aiming for pregnancy or embarking on assisted conception. Given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially attenuate risk may be required, which will inevitably impact patients wellbeing and overall success rates. A questionnaire was developed to explore patients perspectives on different aspects of their fertility treatment during the COVID-19 pandemic. The questionnaire contains the following sections: - demographic variables; - questions regarding the fertility history of the respondent; - questions regarding the impact of fertility treatment cancellation / postponing fertility treatment during COVID-19 on their life, psychological wellbeing and relationship; - questions regarding continuing medical treatment on their own, or seeking treatment elsewhere; - questions regarding the satisfaction of measures taken by their fertility center regarding the COVID-19 pandemic; - questions regarding expectations of further treatments, with focus on safety issues related to the COVID-19 pandemic. Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.

NCT04396210 Coronavirus COVID ART Fertility Issues Other: Questionnaire
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Measure: Patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

Measure: Patients reproductive behaviour by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

Measure: Patients views on resuming fertility treatment by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

4 Determining the Reproductive Health of Men Post-COVID-19 Infection

Study rationale 1. An increasing proportion of the worldwide population is being infected with COVID-19. 2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health. 3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken. 4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.

NCT04414904 Infertility, Male Testosterone Deficiency Other: Exposure: Covid-19 infection
MeSH:Infertility Infertility, Male
HPO:Infertility Male infertility

Primary Outcomes

Description: Sperm concentration (x10^6/ml) between case and control group.

Measure: Semen parameters

Time: 3 visits (up to 75 days apart)

Description: Sperm Motility (%) between case and control group.

Measure: Sperm Parameters

Time: 3 visits (up to 75 days apart)

Description: Sperm normal morphology (%) between case and control group.

Measure: Sperm Parameters

Time: 3 visits (up to 75 days apart)

Description: Testosterone (nmol/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Description: Follicle Stimulating Hormone(IU/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Description: Luteinising hormone(IU/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Secondary Outcomes

Description: Compare seminal reactive oxidative species (RLU/second/10^6sperm) between case and control group.

Measure: Seminal Reactive oxygen species

Time: 3 visits (up to 75 days apart)

Description: Compare Sperm DNA fragmentation rate (%) between case and control group.

Measure: Sperm DNA fragmentation rate

Time: 3 visits (up to 75 days apart)

5 Detection of SARS-CoV-2 in Follicular Fluid and Cumu-lus-oocyte-complexes From COVID-19 Patients During Controlled Ovarian Stimulation for ICSI Treatment

Recently, the world was shaken awake by a pandemic caused by a novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). In most nations drastic isolation measures were taken to minimize the further spread of the Coronavirus Disease 2019 (COVID-19). Being the first pandemic sparked by a Coronavirus, little was known on COVID-19 and its implications on general health. Our understanding on the virus and its potential effects on health is growing. In Belgium, the situation is stabilizing, and doctors and healthcare workers are slowly recommencing routine work and consultations. As also fertility treatments were abruptly interrupted, many patients are in need to resume their treatment. The limited evidence of SARS-CoV-2 on pregnancy seems to be rather satisfying1, but practically nothing is known about the possible impact of an active SARS-CoV-2 infection on female gametes. Viral transmission occurs predominantly through respiratory droplets, but transmission to gametes cannot be ruled out. Since the onset of the pandemic, knowledge about the molecular details of SARS-CoV-2 infection rapidly grew. Coronaviruses are enveloped RNA viruses. For a virus to deliver their genome into the host cell, attachment and entrance into that cell is a crucial step. The coronavirus surface protein spike (S) mediates entry into target cells by binding to a cellular receptor and subsequent fusing of the viral envelope with a host cell membrane. The SARS-CoV-2-S protein (SARS-S) utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor for host cell entry. Host proteases such as transmembrane serine protease 2 (TMPRSS2) are then needed to cleave the viral S protein, allow-ing permanent fusion of the viral and host cell membranes2. Expression of ACE2 and TMPRSS2 has been shown in testicular, uterine and placental cells. Based on available transcriptomic data, co-expression of ACE2 and TMPRSS2 is also seen on oocyte level, but the possible impact on reproduction is unknown. The BSG (basigin or CD147), a receptor on host cells, was also identified as a possible route for viral invasion.

NCT04425317 Infertility COVID IVF Diagnostic Test: Blood sample
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Description: Identification of viral RNA in cumulus-oocyte-complexes, exclusively looking at the material that is considered waste material in a normal oocyte retrieval

Measure: Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium

Time: 1 day

Secondary Outcomes

Description: Presence of receptors, identified as possible steps in the entry pathway for SARS-CoV-2

Measure: Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometrium

Time: 1 day

6 Assessing the Perception and the Personal Experience of the COVID19 Pandemic Among Infertile Couples Undergoing Assisted Reproductive Treatment (ART)

Non-urgent medical care, such as fertility treatments, has been massively postponed during the past weeks due to the COVID19 pandemic. The lockdown and the closure of IVF centers might cause anxiety and depression among infertile couples, who are already exposed to the distressing experience of infertility and for whom the wait for a baby already appears unending. Few data are available regarding the impact of SARS-CoV-2 on pregnant women and foetus, or on fertility. This study aims to assess the views of infertile couple regarding the potential risks of COVID during their fertility treatment and their personal experience of the COVID pandemic and their expectation for further treatment .

NCT04456010 COVID19 Fertility Issues ART Other: Questionnaire
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Description: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment, via a survey

Measure: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation

Time: 1 day

Secondary Outcomes

Description: . Risk assessment by the patient, via a survey, regarding SARS-CoV-2 during a fertility treatment or during pregnancy. Perception of the risks linked to SARS-CoV-2 during their fertility treatment or during a pregnancy

Measure: Risk assessment

Time: 1 day

Description: Patients'expectations regarding the management of an abrupt closure of the fertility center, via a survey

Measure: Patients'expectations regarding the management of an abrupt closure of the fertility center

Time: 1 day

7 Psychological Impact of COVID19 Among Women Undergoing Infertility Treatment, a French Cohort

In France, one couple in eight encounters difficulties to conceive. The diagnosis of infertility frequently leads to symptoms of anxiety and depression. These symptoms appear to be higher than in the general population. Some recent studies have looked at the relationship between anxiety and depression in ART cares. Results are controversial, but it appears that patients with lower levels of anxiety and depression have higher pregnancy rates. Moreover, in couple, women seem to have more symptoms of anxiety and depression than men. First epidemiological studies related to the COVID 19 pandemic have shown strong psychological impact on the general population with an anxiety rate estimated at more than 30%. With COVID 19 pandemic and cessation of ART, it is highly likely that psychic symptoms of anxiety or even depression may have appeared or worsened in women undergoing infertility treatment.

NCT04496869 Infertility Treatment Women Other: Online questionnaire
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Description: Perceived Stress Scale 10 assess stress in 10 questions with score from 0 to 40. The higher the score is, the more important the stress level is.

Measure: Psychological impact assessed by scores of PSS10 scales.

Time: 15 minutes

Description: depression Scale with 14 questions. It assesses separately anxiety (score from 0 to 21) and depression (score from 0 to 21).The higher the score is, the more important the anxiety level is.

Measure: Psychological impact assessed by scores of HADS scales.

Time: 15 minutes


HPO Nodes